LISATA THERAPEUTICS, INC. — Director's Dealing 2018

Jan 10, 2018

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: CALADRIUS BIOSCIENCES, INC. (CLBS)
CIK: 0000320017
Period of Report: 2018-01-08

Reporting Person: Mazzo David J (Director, Chief Executive Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2018-01-08	Common Stock	A	33300	—	Acquired	96706	Direct
2018-01-08	Common Stock	F	4462	—	Disposed	92244	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2018-01-08	Stock Option	$3.79	A	50000	Acquired	2028-01-08	Common Stock (20000)	Direct

Footnotes

F1: Represents 33,300 shares of restricted stock granted under the Issuer's 2015 Equity Compensation Plan. The restricted stock vests in three equal installments, with one-third of the shares vesting on the date of grant and an additional one-third vesting on each of the first and second anniversaries of the grant date.

F2: Includes 67,269 shares of unvested restricted stock.

F3: One-third of the shares underlying the stock options vest immediately on the grant date, with an additional one-third vesting on each of the first and second anniversaries of the grant date.